The NICHD conducts and supports a variety of clinical research related to Cushing’s syndrome. Select a link below to learn more about these projects.
Featured NICHD Clinical Trials on Cushing’s Syndrome
- New Imaging Modalities in the Evaluation of Patients with Ectopic Cushing’s Syndrome
Between 10% and 20% of patients with hypercortisolism (Cushing’s syndrome) have ectopic production of the hormone ACTH, meaning the hormone is not being released from the normal site, the pituitary gland. The inability to detect the source of ectopic ACTH production often results in unnecessary pituitary surgery or irradiation. Positron emission tomography (PET scan) has the ability to detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This study will test whether [18-F]-fluorodeoxyglucose (FDG) or use of a higher dose of [111In-DTPA-D-Phe]-pentetreotide can be used to successfully localize the source of ectopic ACTH production.
- A Clinical and Genetic Investigation of Pituitary Tumors and Related Hypothalmic Disorders
This protocol has several aims, including the development of new clinical studies for the recognition and therapy of pituitary tumors, investigation of a new research magnetic resonance imaging (MRI) tool and its usefulness in the identification of pituitary tumors, and investigation of the psychological effects of cortisol secretion in pediatric patients with Cushing’s disease. Continuation of this protocol will eventually lead to new, separate protocols that will address all aspects of diagnosis of pituitary tumors and their therapy in childhood.
- Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions
Presently there are no tests for screening of PPNAD and the Carney Complex. In addition, it is unknown how these conditions are genetically transferred from generation to generation. This study proposes to use standard methods of clinical testing and genetic testing to define the genetic basis for PPNAD and/or the Carney Complex, determine the molecular changes associated with the development of the tumors, identify carriers of the disease, determine the prognosis for carriers and affected individuals, and provide sufficient data for genetic counseling of families with PPNAD and/or Carney Complex.
NICHD Clinical Trials
All NICHD Clinical Trials on Cushing’s syndrome
ClinicalTrials.gov Search Results